コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ed ambiguity between diagnosis of asthma and chronic obstructive lung disease.
2 d by criteria from the Global Initiative for Chronic Obstructive Lung Disease.
3 lating IL-18 were also seen in patients with chronic obstructive lung disease.
4 y macrophages from smokers and patients with chronic obstructive lung disease.
5 lds and triggers exacerbations of asthma and chronic obstructive lung disease.
6 cluding sepsis, asthma, cystic fibrosis, and chronic obstructive lung disease.
7 d tissue samples obtained from patients with chronic obstructive lung disease.
8 ere attributable to heart failure and 12% to chronic obstructive lung disease.
9 ndividuals with preexisting heart failure or chronic obstructive lung disease.
10 de accumulation mediates the pathogenesis of chronic obstructive lung diseases.
11 ine in ml/yr for GOLD (Global Initiative for Chronic Obstructive Lung Disease) 0-4 was as follows: 41
12 proved drug that has long been used to treat chronic obstructive lung disease and acetaminophen toxic
13 selectively increased in postviral mice with chronic obstructive lung disease and in humans with very
14 Smoking is the greatest risk factor for both chronic obstructive lung disease and interstitial lung d
15 nflammatory lung diseases, including asthma, chronic obstructive lung disease, and cystic fibrosis, w
16 chronic respiratory diseases such as asthma, chronic obstructive lung disease, and cystic fibrosis.
17 cluding acute respiratory distress syndrome, chronic obstructive lung disease, and idiopathic pulmona
18 rates, and lung volumes in 29 patients with chronic obstructive lung disease before lung-volume-redu
21 nsmokers, normal smokers, smokers with early chronic obstructive lung disease (COPD), and smokers wit
23 tudy and met the GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria for COPD with
25 OPD was defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criterion (FEV(1
26 cipants (n = 116) with Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade U (unclass
27 vs 24%) for those with Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades C-D (n =
28 m, and since 2001, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published it
29 inety-nine patients in Global Initiative for Chronic Obstructive Lung Disease (GOLD) II, 85 in GOLD I
30 e characterised by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric cate
31 ere as follows: having Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 3 or 4 dis
34 5 patients with COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 4) and 28
35 11 patients with GOLD [Global Initiative for Chronic Obstructive Lung Disease] grade 1B COPD, 11 age-
37 1.54; confidence interval [CI], 1.12-2.10), chronic obstructive lung disease (HR, 1.56; CI, 1.15-2.1
38 e to very severe COPD (Global Initiative for Chronic Obstructive Lung Disease III/IV) compared with b
41 (VMR) patterns in eight patients with severe chronic obstructive lung disease (median FEV1 = 0.79 L,
42 omen who did not have heart disease, stroke, chronic obstructive lung disease, or cancer at the time
43 T for inflammatory disease, transplantation, chronic obstructive lung disease, other cancers, and hyp
44 of guidelines from the Global Initiative for Chronic Obstructive Lung Disease reorganised treatment o
45 Initiative for Asthma/Global Initiative for Chronic Obstructive Lung Disease report, to provide heal
47 participants (11%) met Global Initiative for Chronic Obstructive Lung Disease spirometric criteria fo
48 the greatest effect in Global Initiative for Chronic Obstructive Lung Disease stage 1, where each exa
49 fects were observed in Global Initiative for Chronic Obstructive Lung Disease stage 2 and 3 subjects.
50 Twenty subjects with Global Initiative for Chronic Obstructive Lung Disease stage I COPD and 20 hea
51 om patients with COPD (Global Initiative for Chronic Obstructive Lung Disease stage I to II) before a
52 ted from patients with Global Initiative for Chronic Obstructive Lung Disease stage I-IV COPD, and sm
53 wo patients with COPD (Global Initiative for Chronic Obstructive Lung Disease stage II-IV) underwent
55 Older age and milder Global Initiative for Chronic Obstructive Lung Disease stage were associated w
56 d emphysema, increased Global Initiative for Chronic Obstructive Lung Disease stage, and COPD disease
58 persistent wheeze, and Global Initiative for Chronic Obstructive Lung Disease stages 2 and higher chr
59 nts (aged >/=40 years, Global Initiative for Chronic Obstructive Lung Disease stages III-IV, and one
61 5.3 [8.2] years, GOLD (Global Initiative for Chronic Obstructive Lung Disease) stages I-IV: 9.4, 42.5
62 estimates based on the Global Initiative for Chronic Obstructive Lung Disease staging criteria were a
63 rrogate Endpoints), and GenKOLS (Genetics of Chronic Obstructive Lung Disease) studies were analyzed.
64 Bronchiolitis obliterans is a rare form of chronic obstructive lung disease that follows a severe i
65 disease, hypertension, diabetes mellitus, or chronic obstructive lung disease), the age-adjusted haza
66 ulmonary disease (COPD) are highly prevalent chronic obstructive lung diseases with an associated hig
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。